Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Weitz, J.I.
    A novel approach to thrombin inhibition (2003), Thromb. Res., 109 Suppl 1, S17-22.
    View publication on PubMed

Application

EC Number Application Comment Organism
3.4.21.5 medicine enzyme inhibitors are used in therapy and prevention of venous and arterial thrombosis, inhibition mode, efficiency and safety, overview Homo sapiens

Inhibitors

EC Number Inhibitors Comment Organism Structure
3.4.21.5 antithrombin inactive if complexed with heparin Homo sapiens
3.4.21.5 argatroban small site-directed direct thrombin inhibitor Homo sapiens
3.4.21.5 bivalirudin synthetic hirudin derivative Homo sapiens
3.4.21.5 efegatran small site-directed direct thrombin inhibitor Homo sapiens
3.4.21.5 heparin inactive if complexed with antithrombin Homo sapiens
3.4.21.5 Hirudin irreversible, direct thrombin inhibitor, competitive to fibrin, noncompetitive to fibrin Homo sapiens
3.4.21.5 melagatran reversible, active site directed direct thrombin inhibitor, active form of ximelagatran Homo sapiens
3.4.21.5 additional information schematic representation of inhibition mode Homo sapiens

Localization

EC Number Localization Comment Organism GeneOntology No. Textmining
3.4.21.5 extracellular bound to fibrin or soluble Homo sapiens
-
-

Organism

EC Number Organism UniProt Comment Textmining
3.4.21.5 Homo sapiens
-
-
-

Source Tissue

EC Number Source Tissue Comment Organism Textmining
3.4.21.5 plasma extracellular, bound to fibrin or soluble Homo sapiens
-

Substrates and Products (Substrate)

EC Number Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
3.4.21.5 thrombin-activable finrinolysis inhibitor + H2O i.e. TAFI Homo sapiens ?
-
 ?